Ozempic vs. Wegovy: Which Is Better? Side-by-Side Comparison

Which is better, Ozempic or Wegovy? If your main goal is to lose weight and keep it off, Wegovy is generally the better choice. It’s specifically FDA-approved for chronic weight management and uses semaglutide at doses studied for substantial weight loss.

However, if your main goal is to control blood sugar while managing type 2 diabetes, Ozempic may be the better option because it’s specifically approved for diabetes treatment.

But both medications have additional advantages. For example, if you have type 2 diabetes and chronic kidney disease, Ozempic may be a better choice because it’s FDA-approved to reduce the risk of certain serious kidney complications.

Wegovy, on the other hand, is also FDA-approved to reduce the risk of major cardiovascular events in eligible adults with established cardiovascular disease and obesity or overweight.

So, which one should you choose? It depends on what you’re trying to accomplish and your medical history. Interestingly, Ozempic and Wegovy contain the same active ingredient, semaglutide, and work through the same GLP-1 receptor mechanism. The biggest differences are their FDA-approved uses, dosing regimens, and treatment goals.

Ultimately, the best choice is the medication that addresses your health priorities while being safe and appropriate for your individual needs.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Ozempic?

Ozempic (semaglutide) is a prescription GLP-1 receptor agonist primarily used to improve blood sugar control in adults with type 2 diabetes. It also reduces the risk of major cardiovascular events in eligible adults with type 2 diabetes and certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease.

Ozempic works by stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It can also reduce appetite and promote weight loss, although Ozempic is not FDA-approved specifically for weight management.

ozempic

What Is Wegovy?

Wegovy (semaglutide) is a prescription GLP-1 receptor agonist FDA-approved for chronic weight management in eligible adults with obesity or overweight and at least one weight-related medical condition. 

Wegovy injections are also approved for weight management in adolescents aged 12 and older with obesity. Wegovy is available as a once-weekly injection and a once-daily oral tablet, although approved uses differ by formulation.

Wegovy works by activating GLP-1 receptors involved in appetite regulation, helping patients feel fuller, reduce food intake, and lose weight. Beyond weight management, Wegovy is approved to reduce major cardiovascular events in eligible adults with established cardiovascular disease and obesity or overweight. 

Its injectable formulation is also approved for certain adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis.

Wegovy

Ozempic vs. Wegovy: Side by Side Comparison

Ozempic and Wegovy contain the same active ingredient, semaglutide, but are approved for different primary treatment goals. Ozempic focuses on type 2 diabetes management and certain cardiovascular and kidney outcomes, while Wegovy focuses on long-term weight management and additional weight-related health conditions. Their dosing, clinical trial results, insurance coverage, and approved patient populations also differ.

Comparison Ozempic Wegovy
Manufacturer Novo Nordisk Novo Nordisk
Pricing

Manufacturer self-pay offers:

  • Introductory Offer: $199/month for the first two months of eligible new injection prescriptions at 0.25 mg or 0.5 mg.
  • Standard Injection Offers: $349/month for 0.25 mg, 0.5 mg, or 1 mg; $499/month for 2 mg.
  • Oral Formulation: Manufacturer self-pay offers start at $149/month, depending on dosage and eligibility.

Retail prices may be higher.

Manufacturer self-pay offers:

  • Introductory Injection Offer: $199/month for the first two months of eligible new prescriptions at 0.25 mg or 0.5 mg.
  • Standard Injection Offers: $349/month for doses through 2.4 mg; $399/month for Wegovy HD 7.2 mg.
  • Oral Formulation: $149/month for 1.5 mg, $199/month for 4 mg, and $299/month for 9 mg or 25 mg through eligible self-pay programs.

Retail prices may be higher.

Insurance Coverage
  • Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available for medically eligible beneficiaries.
  • Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
  • Commercial Insurance: Some plans cover Wegovy for eligible patients with obesity, overweight, or other approved indications.
  • Prior Authorization: Medical eligibility, BMI documentation, and supporting health information may be required.
  • Medicare: Certain beneficiaries may qualify for covered indications or the Medicare GLP-1 Bridge program, subject to eligibility and plan requirements.
  • Savings Programs: Eligible commercially insured patients may pay as little as $25/month.
Main Purpose Improve blood sugar control in adults with type 2 diabetes. Long-term weight loss and weight maintenance in eligible patients with obesity or overweight and qualifying weight-related conditions.
Secondary Purposes
  • Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes.
  • Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
  • Liver Health: Wegovy injections are approved for certain adults with MASH and moderate to advanced liver fibrosis.
  • Adolescent Weight Management: Wegovy injections are approved for adolescents aged 12 and older with obesity.
Active Ingredient Semaglutide, a GLP-1 receptor agonist. Semaglutide, a GLP-1 receptor agonist. The same active ingredient as Ozempic.
Benefits
  • Blood Sugar Control: Lowers blood glucose and HbA1c.
  • Weight Management: May promote weight loss.
  • Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
  • Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
  • Weight Loss: Produces substantial average weight reduction in eligible patients.
  • Appetite Regulation: Helps reduce hunger and food intake.
  • Cardiovascular Health: Reduces major cardiovascular events in eligible adults with established cardiovascular disease.
  • Liver Health: May improve MASH and liver fibrosis outcomes in the approved adult population when using the indicated injectable formulation.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Possible worsening of diabetic retinopathy.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Diabetic retinopathy complications may occur in patients with diabetes.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss Potential Can produce clinically meaningful weight loss, but results depend on dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. Wegovy 2.4 mg injections produced approximately 15% average weight loss after 68 weeks in a major trial involving adults without diabetes. Wegovy 25 mg tablets also demonstrated substantial weight loss in clinical trials. Results vary by formulation, dose, and patient population.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Oral Tablet: Once-daily oral formulation with specific administration instructions.
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Oral Tablet: Once-daily tablet taken on an empty stomach with water, followed by at least 30 minutes before food, beverages, or other oral medications.
Dosing Considerations
  • Starting Injection Dose: Typically 0.25 mg weekly.
  • Dose Escalation: Gradual increases based on treatment response and tolerability.
  • Maximum Injection Dose: 2 mg weekly for adults.
  • Oral Dosing: Follows a separate daily dosing schedule.
  • Starting Injection Dose: Typically 0.25 mg weekly.
  • Injection Maintenance Doses: Commonly 1.7 mg or 2.4 mg weekly, with Wegovy HD 7.2 mg available for eligible adults.
  • Oral Starting Dose: 1.5 mg once daily, followed by gradual dose escalation.
  • Oral Maintenance Dose: 25 mg once daily for approved adult weight-management and cardiovascular indications.
Who May Benefit Most? Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications. Adults with obesity or qualifying overweight who need long-term weight management; adolescents aged 12 and older with obesity who qualify for injections; and adults who meet its cardiovascular or MASH treatment indications.
How Fast Does It Work?
  • Blood Sugar: Improvements may begin within the first weeks.
  • HbA1c: Reductions are generally assessed over approximately 3 months.
  • Weight Loss: Typically develops gradually over several months.
  • Appetite: Changes may begin within the first several weeks.
  • Initial Weight Loss: May become noticeable within the first several weeks.
  • Substantial Weight Loss: Generally develops over several months, with major clinical trials evaluating outcomes over approximately 64–68 weeks or longer.
Potential Side Effects
  • Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
  • Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion.
  • Other Effects: Headache, fatigue, dizziness, and possible injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.

Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 6, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional.

Important: Both medications contain semaglutide and carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown.

Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Ozempic and Wegovy should not be taken together because they contain the same active ingredient. Treatment selection requires an individualized medical assessment.

Weight-loss evidence: In the STEP 1 clinical trial, semaglutide 2.4 mg administered once weekly produced approximately 14.9% average body-weight reduction after 68 weeks in adults with obesity or overweight without diabetes, compared with approximately 2.4% with placebo.

The OASIS 4 trial also demonstrated substantial weight loss with oral semaglutide 25 mg. These studies support Wegovy’s effectiveness for weight management, but they do not represent direct head-to-head comparisons between the Ozempic and Wegovy brands. Because both contain semaglutide, differences in weight-loss outcomes depend on factors such as dose, formulation, patient population, and treatment duration.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Ozempic and Wegovy. It is not a substitute for professional medical advice, diagnosis, or treatment.

The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.

Related Ozempic Content

Related Wegovy Content